Back to Screener

Healthcare

Sagimet Biosciences Inc.(SGMT)

Live Price

Offline

$6.68

+2.30% today

1Y Change

-23.39%

Window

Jun 20, 2025 โ†’ Jun 18, 2026

Market Cap
$240.00M
Revenue Growth
0.0%
EPS Growth
-9.0%
Dividend Yield
0.0%

Coverage: 250 bars ยท Jun 20, 2025 โ†’ Jun 18, 2026

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

Sagimet Biosciences Inc. (SGMT) is a Healthcare stock with a market cap of $240.00M and listed on NASDAQ. The stock last traded around $6.68 and down 23.4% across the available one-year price window (Jun 20, 2025 โ†’ Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of -9.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS -9.0%, free cash flow -7.6% with operating margin 0.0% and ROIC -51.0%. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SGMT price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.

Sector Context

How this name stacks up against nearby peers on first-pass metrics.

Revenue Growth

Below sector median

0.0% vs +7.6% peer median

Operating Margin

Below sector median

0.0% vs +19.4% peer median

What Changed This Quarter

Latest report context and the signals most likely to have changed the story.

Latest report landed above expectations

2026 was reported on May 12, 2026 with an EPS surprise of +15.4%.

The operating picture looks softer than before

Revenue is at 0.0% and EPS is at -9.0%, with operating margin around 0.0%.

The next real check-in already has a date

The next earnings event is scheduled for Aug 12, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.

Earnings Reaction Memory

How the stock has tended to move after recent reports.

Across the last 3 reported quarters, the stock averaged -12.0% over the next 5 trading days and finished higher after 0 of those reports.

View quarter-by-quarter reaction table
QuarterEPS ฮ”1D5D20D
2026
May 12, 2026
+15.4%-0.7%-14.5%-15.0%
2026
Mar 11, 2026
+32.6%-7.0%-15.3%-1.7%
2025
Nov 13, 2025
+2.4%+0.1%-6.1%-19.5%

Benchmark Comparison

Normalized Performance vs SPY

Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.

1Y shared range

SGMT

โ€”

Normalized return

SPY

โ€”

S&P 500

Excess Return

โ€”

Relative to SPY

SGMT Max Drawdown

-55.57%

Trailing 1Y

SPY Max Drawdown

โ€”

Trailing 1Y

Benchmark comparison is loading or unavailable right now.

Calendar-Year Returns

Uses the longest available daily history for SGMT and SPY.

Calendar-year return history is still loading or unavailable.
Sagimet Biosciences Inc. logo

Company Overview

Sagimet Biosciences Inc.

NASDAQ Global Market

San Mateo, CA, US
Visit sagimet.comCall IR650-561-8600

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

Leadership
David A. Happel
IPO Date
Jul 17, 2023
Employees
14
Street Address
155 Bovet Road
Mailing
San Mateo, CA, 94402
Region
San Mateo, CA, US
Reporting Currency
USD
Investor Line
650-561-8600
Last Updated
May 4, 2026
CIK: 0001400118ISIN: US7867001049CUSIP: 786700104
Reports in USDSEC Registered

Key Fundamentals

Valuation, growth, profitability, and balance sheet signals.

Valuation

P/E
โ€”
EV/EBITDA
โ€”
Price/Sales
โ€”
Price/Book
2.2

Growth

Revenue
0.0%
EPS
-9.0%
Free Cash Flow
-7.6%

Profitability

Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-40.8%
ROIC
-51.0%

Balance Sheet

Debt/Equity
0.00
Current Ratio
22.82

Earnings Reports

๐Ÿ“… Next earningsAug 12, 2026
PeriodB/MEPSEPS ฮ”RevenueRev ฮ”
โ€”
Aug 12, 26
TBD
โ€”
Est -0.26
โ€”
โ€”
Est โ€”
โ€”
โ€”
May 12, 26
โœ“
-0.33
Est -0.39
+15.4%
โ€”
Est โ€”
โ€”
โ€”
Mar 11, 26
โœ“
-0.29
Est -0.43
+32.6%
โ€”
Est 1111.1B
โ€”
โ€”
Nov 13, 25
โœ“
-0.40
Est -0.41
+2.4%
โ€”
Est โ€”
โ€”
โ€”
Aug 13, 25
โœ“
-0.32
Est -0.52
+38.5%
โ€”
Est โ€”
โ€”
โ€”
May 8, 25
โœ“
-0.56
Est -0.79
+29.1%
โ€”
Est โ€”
โ€”
โ€”
Mar 12, 25
โœ“
-0.50
Est -0.65
+23.1%
โ€”
Est โ€”
โ€”
โ€”
Nov 14, 24
โœ“
-0.45
Est -0.47
+4.3%
โ€”
Est โ€”
โ€”
โ€”
Aug 14, 24
โœ“
-0.25
Est -0.34
+26.5%
โ€”
Est โ€”
โ€”
โ€”
May 15, 24
โœ“
-0.23
Est -0.41
+43.9%
โ€”
Est โ€”
โ€”
โ€”
Mar 25, 24
โœ—
-0.78
Est -0.58
-34.5%
โ€”
Est โ€”
โ€”
โ€”
Nov 13, 23
โœ“
-0.35
Est -1.02
+65.7%
2000.0B
Est โ€”
โ€”
โ€”
Jul 14, 23
โœ—
-35.80
Est -0.50
-7060.0%
โ€”
Est โ€”
โ€”
โ€”
Mar 31, 23
-0.30
Est โ€”
โ€”
โ€”
Est โ€”
โ€”
โ€”
Dec 31, 22
-0.32
Est โ€”
โ€”
โ€”
Est โ€”
โ€”
โ€”
Sep 30, 22
-0.34
Est โ€”
โ€”
โ€”
Est โ€”
โ€”

Latest News

No news articles available

Official Releases

Company announcements and filings-style updates.

Official
No official releases available

Next Step

Keep the research moving

After the overview, the strongest next step is usually chart context or a tighter compare set.

Explore the advanced chart guideRead how to compare stocks